Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16766949 | 1.00 | BTK (0.41) | BTKAAK1EGFRCTSBCTSS | |
| SCHEMBL16765885 | 0.85 | BTK (0.53) | BTKEGFR | |
| SCHEMBL16765813 | 0.84 | BTK (0.43) | BTKEGFR | |
| SCHEMBL16790980 | 0.83 | BTK (0.41) | BTKMAPTSYK | |
| SCHEMBL16790979 | 0.81 | BTK (0.36) | BTKSYK | |
| SCHEMBL16798105 | 0.81 | BTK (0.36) | BTKSYK | |
| Hydrochloric Acid SCHEMBL16766505 | 0.81 | BTK (0.36) | BTKSYK | |
| Hydrochloric Acid SCHEMBL16766503 | 0.81 | BTK (0.36) | BTKSYK | |
| SCHEMBL16766340 | 0.79 | BTK (0.41) | BTKAAK1MKNK2 | |
| SCHEMBL107748 | 0.78 | MAPK8 (0.45) | BTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| EP-3077384-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | HOFFMANN LA ROCHE (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260415-B2 | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality | GENENTECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158846-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | BTK, TYK2, LCK | BTK 1/4885AAK1 682/4885EGFR 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.